This page shows the latest dostarlimab news and features for those working in and with pharma, biotech and healthcare.
GSK’s Jemperli (dostarlimab) in combination with chemotherapy has been approved by the US Food and Drug Administration (FDA) for previously untreated, primary advanced or recurrent endometrial cancer. ... Last month, GSK announced that the same patient
GSK has announced that eligible endometrial cancer patients in the UK will be granted early access to its anti-PD-1 therapy Jemperli (dostarlimab) in combination with platinum-containing chemotherapy via
GSK has announced positive results from a planned interim analysis of part one of its phase 3 RUBY trial, investigating Jemperli (dostarlimab) in the treatment of adult patients with primary advanced
identify patients whose solid tumours are deficient in DNA mismatch repair (MMR) and who may benefit from GSK’s anti-PD-1 immunotherapy treatment Jemperli (dostarlimab-gxly).
GSK and iTeos are also planning to launch combination studies of the mAb with PD-1 inhibitor Jemperli (dostarlimab) in 2022.
The Food and Drug Administration (FDA) has approved Jemperli(dostarlimab-gxly) for the treatment of adult patients with mismatch repair-deficient (dMMR) recurrent or advanced endometrial cancer, following an FDA-approved
More from news
Approximately 1 fully matching, plus 10 partially matching documents found.
No results were found
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...